Science_TechSocial_Issues
News 1 of 26

Wockhardt's ZAYNICH Becomes First Indian-Developed Antibiotic to Get US FDA Approval for Complicated UTIs

Target:UPSC GS-IIIMPSCTeachingSSC GAPrelims HighMains HighStatic GK Link
23 Jun 2026
~2 min
Source: Indian Express
Key Data:May 30, 2026 (US FDA approval)May 27, 2026 (DCGI approval)17 years development200 researchers530 patients in Phase III trial$12,000-$15,000 US treatment cost
Bodies:US FDADrugs Controller General of India (DCGI)Wockhardt
Practice MCQs from today's news ▸
What This Article Covers

1.Wockhardt's ZAYNICH™ (cefepime/zidebactam) approved by US FDA on May 30, 2026 for complicated urinary tract infections caused by Gram-negative bacteria.

2.Developed over 17 years at Chhatrapati Sambhajinagar research centre with 200 researchers; Phase III trial involved 530 patients across 64 sites globally.

3.AMR kills ~300,000 Indians annually; ZAYNICH offers a safer alternative to colistin, with compassionate-use survival over 90% and India pricing 75-80% lower than US ($12,000-$15,000).

The Big Picture
Prelims · HighMains · High

India has achieved a historic milestone as Wockhardt's novel antibiotic ZAYNICH (cefepime + zidebactam) received US FDA approval – the first new chemical entity fully discovered and developed by an Indian company to get this clearance. This breakthrough offers safer options against multidrug-resistant Gram-negative infections, directly addressing the global antimicrobial resistance (AMR) crisis. For exam aspirants, this is a high-yield topic linking science, health policy, and India's pharma ecosystem.

Exam Lens

Quick Exam Facts From News

Drug NameZAYNICH™ (cefepime and zidebactam)
DeveloperWockhardt Ltd.
US FDA Approval DateMay 30, 2026
DCGI Approval DateMay 27, 2026
Development Time & Team17 years, 200 researchers
Phase III Trial Size530 patients, 64 sites (US, Europe, Latin America, China, India)
US Treatment Cost$12,000 – $15,000
India Pricing vs US75-80% lower
Compassionate Use Survival>90% (80+ patients)
Annual AMR Deaths in India~300,000 (UTIs ~25%)
Drug ClassBeta-lactam enhancer (new class)

1-Minute Revision

  • ›Drug Name: ZAYNICH™ (cefepime and zidebactam)
  • ›Developer: Wockhardt Ltd.
  • ›Target this Data: US FDA approval date – May 30, 2026; DCGI approval – May 27, 2026.
  • ›Target this Drug: ZAYNICH (cefepime + zidebactam) – first Indian-developed US FDA-approved antibiotic.
  • ›Target this Nodal Body: Drugs Controller General of India (DCGI) and US Food and Drug Administration (FDA).
  • ›Target this Location: Research centre in Chhatrapati Sambhajinagar, Maharashtra (earlier Aurangabad).

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

Q1Static LinkageEasy

Which Indian regulatory body granted approval to Wockhardt's ZAYNICH for use in India on May 27, 2026?

Q2Statement-basedHard

Consider the following statements regarding Wockhardt's antibiotic ZAYNICH:

1. ZAYNICH is a novel oral antibiotic primarily effective against Gram-positive bacteria.

2. The drug was developed at Wockhardt's research centre in Pune, Maharashtra.

3. The US FDA approved ZAYNICH in May 2026 for treating complicated urinary tract infections caused by Gram-negative bacteria.

Which of the statements given above is/are correct?

Q3Data-centricMedium

According to the article, what is the estimated annual number of deaths in India from all multidrug-resistant infections (not just UTIs)?

Q4Application/ImpactMedium

What is the key advantage of ZAYNICH over the existing drug colistin for treating multidrug-resistant Gram-negative infections?

All 20 MCQs ▸
You finished this topic
Explore Related Topics
Related Current Affairs
Science & Tech Current Affairs

India Gets First Disease-Modifying Alzheimer's Drug Leqembi After CDSCO Nod

Eisai's Leqembi (lecanemab), India's first disease-modifying therapy for early Alzheimer's, has been launched after CDSCO approval. This marks a shift from symptomatic to disease-modifying treatment, but challenges of early diagnosis, biomarker infrastructure, and affordability remain significant.

Science & Tech Current Affairs

IISc SraVaani: India's First Open-Source Speech Recognition Model for 65 Languages

IISc's SPIRE Lab, in collaboration with ARTPARK and Google, has released SraVaani – the first multilingual Indian speech recognition model trained on 65 languages and dialects. It extends ASR to 45 underserved regional languages, potentially benefiting 25 crore people. This marks a major step in inclusive AI for India's linguistic diversity.

Science & Tech Current Affairs

CDSCO Approves Qdenga: India's First Dengue Vaccine to be Distributed by Dr Reddy's from 2027

India’s first approved dengue vaccine Qdenga will enter the private market in 2027 via Dr Reddy’s, after CDSCO approval in July 2026. The vaccine is effective against all four serotypes, requires no pre-vaccination screening, and shows 61.2% efficacy against dengue and 84.1% against hospitalization. This is a landmark step in India's fight against dengue.

Science & Tech Current Affairs

ISRO Launches EOS-05: India's First Geo-Imaging Satellite in Geosynchronous Orbit; SC Invokes Article 142 to Quash CJP Protest Cases

A day of high exam relevance: ISRO successfully launched EOS-05, India’s first dedicated geo-imaging satellite in geosynchronous orbit, breaking a failure streak. The Supreme Court used its extraordinary power under Article 142 to close cases linked to CJP protests, raising important constitutional questions. Other key updates include OpenAI’s new autonomous AI model, Manipur’s NRC-first demand for Census deferral, mistrust in GDP data, and Tata Chemicals’ Kenya dispute.

Polity Current Affairs

MeitY Summons Meta Global Team Over Algorithmic Bias; Parliamentary Panel to Question

Government summons Meta's global team to clarify algorithmic bias and role in public order after MeitY rejects technical glitch explanation. Parliamentary panel will also question the company. This highlights growing regulatory scrutiny on social media algorithms and their societal impact.

Social Issues Current Affairs

NOTTO Reports 20,000+ Transplants in 2025, Launches Portal and Swap Guidelines

NOTTO released 2025 data showing over 20,000 transplants, persistent gender disparity in organ donation (68% female donors vs 78% male recipients), and launched a new digital portal to enhance transparency. New swap transplantation guidelines aim to expand matching beyond single hospitals, but legal recognition under THOTA is still pending.

Science & Tech Current Affairs

IARC Classifies Three WHO Essential Medicines as Group 1 Carcinogens: Hydrochlorothiazide, Voriconazole, Tacrolimus

IARC, the WHO cancer research agency, has classified three widely used drugs—hydrochlorothiazide, voriconazole, and tacrolimus—as Group 1 carcinogens. Despite this, experts stress that patients should not stop treatment as the benefits for hypertension, fungal infections, and organ transplant rejection far outweigh the cancer risk. The drugs are on the WHO Model List of Essential Medicines and are commonly prescribed in India.

Science & Tech Current Affairs

US FDA Approves First mRNA Flu Shot mFlusiva for Adults 50+ with 26.6% Higher Efficacy

US FDA has approved Moderna's mFlusiva, the first mRNA-based flu vaccine, for adults aged 50 and older. The vaccine demonstrated 26.6% higher efficacy than standard flu shots in a large late-stage trial. This marks a milestone in mRNA technology beyond COVID-19 and is a key topic for Science & Tech and Health sections.